GLP-1 myths vs facts
The most common GLP-1 claims, fact-checked against primary sources. Every verdict links to the FDA, NIH, or peer-reviewed evidence behind it.
The short version
Compounded GLP-1 is notFDA-approved and is not “the same as” the brand drug[1]. GLP-1s like Wegovy and Zepbound are approved for weight management, not only diabetes[2]. And the weight lost in trials is real body weight, not water[3] — though regain after stopping is common.
Claim
“Compounded semaglutide is FDA-approved.”
Verdict: False
Compounded drugs are NOT FDA-approved. The FDA does not review compounded semaglutide for safety, effectiveness, or quality before it is dispensed; quality depends on the compounding pharmacy.
Source: U.S. FDA
Claim
“GLP-1 medications are only for people with diabetes.”
Verdict: False
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in eligible adults (BMI ≥30, or ≥27 with a weight-related condition) — not only diabetes.
Source: U.S. FDA / NIH MedlinePlus
Claim
“Compounded GLP-1 is the same as the brand drug.”
Verdict: False
Compounded versions use the same active ingredient but are not the same finished product: they are not FDA-reviewed for safety, quality, or effectiveness, and formulations/quality vary by pharmacy. Providers may not claim they are equivalent to Wegovy/Zepbound.
Source: U.S. FDA
Claim
“You regain all the weight the moment you stop a GLP-1.”
Verdict: Partly true
Weight regain after stopping is common because these drugs treat a chronic condition — but the amount varies by person and whether lifestyle support continues. Trial extensions show significant (not always total) regain over the following year.
Source: NEJM (STEP trial program)
Claim
“GLP-1 weight loss is just water weight.”
Verdict: False
Pivotal randomized trials measured sustained loss of body weight (including fat mass) over 12–18 months — not transient water weight. GLP-1/GIP agonists reduce appetite and calorie intake.
Source: NEJM (STEP / SURMOUNT trials)
Sources
Educational only, not medical advice — decisions about GLP-1 medications should be made with a licensed clinician. See our sourcing standards.
Further reading (authoritative sources)
- Prescription medications to treat overweight & obesity — NIH — NIDDKGovernment overview of approved weight-management drugs.
- GLP-1 agonists — overview & how they work — NIH — MedlinePlus
- FDA's concerns with unapproved GLP-1 drugs used for weight loss — U.S. FDA
- Medicaid coverage of and spending on GLP-1s — KFFState-by-state coverage data (2026).